SCHEDULE: Vanguard Discloses 5.05% Stake in Arrowhead Pharmaceuticals

Vanguard Capital Management has reported beneficial ownership of 5.05% of Arrowhead Pharmaceuticals Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 7,081,293 shares of Arrowhead Pharmaceuticals Inc. common stock.
• This holding represents 5.05% of the total class of securities.
• The filing indicates that Vanguard Capital Management has sole dispositive power over these shares.
• Vanguard Capital Management also has sole voting power over 1,048,877 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine ownership disclosure and does not provide new operational or financial information about the company itself.

Positives

• Vanguard's significant stake suggests confidence in Arrowhead Pharmaceuticals' long-term prospects.
• The reporting of sole dispositive power indicates direct control over the investment decisions for these shares.

Negatives

• The filing does not contain any negative financial or operational information about Arrowhead Pharmaceuticals.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks faced by the company.
• The concentration of ownership by a large institutional investor could potentially influence corporate decisions, though the filing certifies these shares were not acquired for the purpose of changing control.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Arrowhead Pharmaceuticals.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by major asset managers like Vanguard often signal a belief in the target company's growth potential within the biotechnology sector, particularly for companies with promising drug pipelines.

Comparison to Industry Standards

• Institutional ownership stakes of 5% or more are common for publicly traded companies, especially in the biotechnology sector where large funds often invest.
• Vanguard's reporting is in line with standard Schedule 13G disclosures for passive investors exceeding the 5% ownership threshold.

Stakeholder Impact

• Shareholders may view Vanguard's investment as a positive signal of institutional confidence.
• Management of Arrowhead Pharmaceuticals will be aware of Vanguard's significant ownership position.

Next Steps

• Vanguard will continue to hold or manage its stake in Arrowhead Pharmaceuticals.
• Arrowhead Pharmaceuticals will continue its operations and disclosures as usual.

Key Dates

Keywords

Arrowhead Pharmaceuticals, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Vanguard Funds